Objective
Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision, and loss of peripheral vision. Current treatments are quite aggressive, are only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited. RetinDR is a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging. The pharmaceutical development of RetinDR is based on the repurposing of the drug substance bosentan (endothelin receptor antagonist, currently indicated for the pulmonary arterial hypertension treatment) for the prevention and treatment of DR.
The global DR market accounted for $5.81B in 2016 and is forecast to grow at 6.3%. CAGR till 2025. We estimate a market share of 0.115% 5 years after commercialisation, equalling revenues of 52M€. Our main business model will focus on sales and distribution of RetinDR in Europe through a distribution agreement with the parent company Medical Mix S.L. and co-development or licensing agreements with strategic industrial partners in markets outside of Europe where we will receive royalties.
With this model and the successful completion of the SME Phase 1 and 2 we estimate an EBITDA of over 55M€ in 5 years after commercialization an IRR of 98% and NPV of over 21M€ considering a WACC of 15%, creating 22 new jobs by 2025. The Feasibility Study for this project will take 6 months and focus on an in-depth market study, technical testing and the development of final business plan to take us to market.
Fields of science
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesclinical medicinepneumology
- medical and health sciencesclinical medicineendocrinologydiabetes
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesclinical medicineophthalmologyretinopathy
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
08174 SANT CUGAT DEL VALLES
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.